Navigation Links
Alba Therapeutics Corporation Reports Preliminary Phase IIa,Clinical Trial Results for AT-1001 for the Treatment of Celiac,Disease

Announces Plans for Advancing AT-1001 into Later Stage Clinical Trials

BALTIMORE, May 07, 2007 /PRNewswire/ -- Alba Therapeutics Corporation today announced preliminary results from its Phase IIa clinical trial for AT-1001 in subjects with Celiac Disease (CD), an autoimmune disease affecting over 3 million people in the United States. Alba's study, the first Phase IIa trial in CD and the first to assess dosing requirements for AT-1001 in CD, was designed to evaluate the safety, tolerability and efficacy of multiple doses of AT-1001 in CD subjects during a 2-week gluten challenge.

The randomized, double-blind, placebo-controlled clinical trial enrolled 86 patients who were confirmed biopsy positive for CD and in compliance with a gluten-free diet for at least six months prior to enrollment. Patients were randomized into seven drug-treated and placebo groups and challenged three times a day with gluten during a 14-day period. Four doses of the enteric coated oral formulation of AT-1001, all less than 10 mg, were given prior to each gluten challenge. Study endpoints included intestinal permeability (IP) -- a marker of disease state in CD -- as well as patient symptoms and outcomes, measured by two validated tests of gastrointestinal disease outcome: the Gastrointestinal Symptoms Rating Scale (GSRS) and the Psychological General Well-Being Index (PGWBI).

    Preliminary analysis revealed the following:


    -- At day 14, IP, as measured by the change in urinary lactulose-to-

       mannitol (LA/MA) ratio, exhibited a dose dependent response.   On day

       21, one week after the final drug dosing and gluten challenge, the dose

       dependent trend continued to statistically significant levels.


    -- The GSRS and PGWBI provided additional efficacy signals that further

       support the IP observations.   Patients on the AT-1001 drug arms

       performed better than those on the gluten/placebo arm.  Analyses

       demonstrated that seve
'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:5/6/2015)... 2015 Research and Markets ( ... "Cannulas Market by Product (Nasal, Arterial, Arthroscopy, ... Material (Plastic, Metal) & End Users (Hospitals, Ambulatory ... report to their offering. The global ... CAGR of 5.6% from 2015 to 2020 to ...
(Date:5/6/2015)... 6, 2015 Fibich, Leebron, Copeland, Briggs & ... settlement has been reached to resolve lawsuits involving individuals ... Actos. Actos - manufactured by Takeda Pharmaceuticals - has ... cancer. Several of the firm,s attorneys were instrumental in ... Tommy Fibich - Founding Partner of Fibich, ...
(Date:5/6/2015)... May 6, 2015  LumiThera Inc., a medical device ... treatment for ocular disorders and disease, today announced Retired ... LumiThera,s Advisory Board to assist in the company,s mission ... "Norm" Dicks was the U.S. Representative for ... and 2013. He is a member of the Democratic ...
Breaking Medicine Technology:Global Cannulas Market 2015 - Forecasts to 2020 with Medtronic, Edward Lifesciences, Terumo, Sorin & Maquet Holding B.V. & Co. Dominating 2Global Cannulas Market 2015 - Forecasts to 2020 with Medtronic, Edward Lifesciences, Terumo, Sorin & Maquet Holding B.V. & Co. Dominating 3Takeda Agrees to $2.4 Billion Settlement for Actos Bladder Cancer Lawsuits 2Retired Congressman Norman Dicks Joins LumiThera's Advisory Team 2
... PALO ALTO, Calif., April 21, 2011 Jazz Pharmaceuticals, Inc. ... host a conference call and live webcast on Tuesday, May ...  During the call, company management will provide a business and ... The live webcast and press release may be accessed ...
... EAST BRUNSWICK, N.J., April 21, 2011 Savient Pharmaceuticals, Inc. ... results for the first quarter 2011 prior to the open ... John H. Johnson, Chief Executive Officer, and David Gionco, ... investment community conference call beginning at 9:00 a.m. Eastern Time ...
Cached Medicine Technology:Savient Pharmaceuticals to Hold First Quarter 2011 Financial Results 2
(Date:5/6/2015)... Los Angeles, CA (PRWEB) May 06, 2015 ... titled “16 Celebrities on Plastic Surgery ,” compiled ... of celebs includes Jennifer Aniston, pop singer Iggy Azalea, ... quote indicates their sentiments about having plastic surgery ... a statement about society and its expectations of youth ...
(Date:5/6/2015)... May 06, 2015 Chesapeake Regional ... state of Virginia to acquire Intuitive Surgical, Inc.’s ... The system upgrade includes enhanced surgical technique capabilities, ... procedures across a wide spectrum of specialties. Its ... pain and quicker recovery times. , “As the ...
(Date:5/6/2015)... 2015 TMG Health, the leading national ... Advantage, Medicare Part D and Managed Medicaid markets, was ... Team category at the BCI North America Awards, a ... the outstanding contribution of business continuity professionals and organizations ... including the USA and Canada. The North America Awards ...
(Date:5/6/2015)... Inversion Studios, a full-service training center ... classes, provides personalized individual instruction and now offers ... new Pilates Ring magic circle. , Inversion Studios ... more centered and graceful, Inversion Studios and its ... healthy fitness through yoga and Pilates. With a ...
(Date:5/6/2015)... San Jose, California (PRWEB) May 06, 2015 ... sales of hand sanitizers are increasing, driven by the ... in preventing the spread of contagious diseases. Hand washing ... a result of consumer apprehension over contracting infections. Periodic ... well as the recent Ebola virus disease ...
Breaking Medicine News(10 mins):Health News:Plastic Surgery: Sixteen Celebrities Offer their Opinion about Going Under the Knife 2Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 2Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 3Health News:TMG Health Recognized by the Business Continuity Institute 2Health News:TMG Health Recognized by the Business Continuity Institute 3Health News:Inversion Studios’ New Pilates Ring Is Circle of Magic for Body, Mind and Spirit 2Health News:Inversion Studios’ New Pilates Ring Is Circle of Magic for Body, Mind and Spirit 3Health News:Growing Apprehension Amid Disease Outbreaks Drives Global Sales of Hand Sanitizers, According to a New Report by Global Industry Analysts, Inc. 2Health News:Growing Apprehension Amid Disease Outbreaks Drives Global Sales of Hand Sanitizers, According to a New Report by Global Industry Analysts, Inc. 3Health News:Growing Apprehension Amid Disease Outbreaks Drives Global Sales of Hand Sanitizers, According to a New Report by Global Industry Analysts, Inc. 4
... It's no surprise that constant stress can make people sick, ... ,A study focused on 119 men and women who were ... caregivers was compared with that of 106 people of similar ... care giving. Blood tests showed that a chemical called Interleukin-6 ...
... million children worldwide die every year, most of them in ... treatments. While the childhood mortality rate in these nations has ... peaked in 1980. About half of the deaths in children ... Pakistan, Democratic Republic of Congo, and Ethiopia) and 90 percent ...
... who are bitten by animals poses little problem for doctors, ... human? ,That’s the question researchers set out to answer in ... and Neck Surgery. Their review of 10 years worth of ... believe can form a standard protocol to follow when man ...
... for preventing disease. In the future, skin ,cancer detection may ... Hattaway is a nine-year ,survivor of melanoma. He’s lucky doctors ... never found a primary, which is what you call the ... the skin. It had already gotten into my lymph system,” ...
... to prevent or delay the onset of prostate cancer, ... cancers. ,More than 18,000 men were randomized , age ... At baseline, digital rectal examination results were normal in ... more than 3.0 ng/mL. Among the 4368 men in ...
... delay the onset of prostate cancer, however, finasteride may ... 18,000 men were randomized , age 55 or older ... rectal examination results were normal in all subjects, and ... ng/mL. Among the 4368 men in the finasteride group ...
Cached Medicine News:
Inquire...
Inquire...
For use with Snap-In Snap-Out-II tip inserts. Available in five styles, the Snap-In Snap-Out-II Laparoscopic Instrument Handles offer the broadest range available....
For use with Snap-In Snap-Out-II tip inserts. Available in five styles, the Snap-In Snap-Out-II Laparoscopic Instrument Handles offer the broadest range available....
Medicine Products: